Welcome to HCPFIVE, your go-to roundup for the latest healthcare news and breakthroughs is specifically curated for busy health professionals.
Each week, we highlight five important developments or headlines from healthcare that you need to know. Whether it's cutting edge treatment, regulatory updates, or innovations that will shape the future of medicine. This week's top stories included new insights into the use of artificial intelligence (AI) in virtual care, a US Food and Drug Administration (FDA) update on the treatment of vision loss, disparities in pediatric kidney transplants, clearance of next-generation glucose monitoring systems, and promising results from psoriasis treatment.
Using HCPFIVE gives you important points to provide information and stay in front of the curve. You can easily dive into the top stories of the week of April 6th, 2025.
Interested in oncology news? Check out oncfive from the sisters' publication Onclive.
Cedars-Sinai research shows that AI tools can improve care in virtual emergency care settings
A new study from Cedars-Sinai found that using artificial intelligence in virtual visits could improve decision-making and compliance with guidelines-oriented care in virtual emergency care settings. Recommendations from AI tools were more often evaluated as better quality when AI and physicians differ, particularly when identifying opportunities to support guidelines adherence care. However, doctors were excellent at adapting recommendations to change information during consultation.
FDA accepts biology license application for wet AMD ONS-5010
The FDA has accepted the OUTLook Therapeutics Resubmission Biology License Application (BLA) for the treatment of wet age-related macular degeneration of ONS-5010. Regulators have flagged the BLA as a Class 2 review and have set the target date for the Prescription Drug User Fail Act (PDUFA) of August 27, 2025 to bevacizumab ophthalmology format.
Socioeconomic status affects preemptive kidney transplant rates in children, the study
Guidelines from Kidney Disease: Improved Global Outcomes (KDIGO) recommends preemptive transplantation in all children with advanced chronic kidney disease. In 2021, only a quarter of children in the incident suffering from ESKD received a preemptive transplant in the United States.
Drawing on data from University of Minnesota kidney transplant recipients, a recent retrospective study found that lower socioeconomic index quartiles were associated with a significantly reduced odds for preemptive transplants.
FDA clears Dexcom G7 15 Days CGM System
The FDA has awarded clearance to the Dexcom G7 15-day continuous glucose monitoring (CGM) system for diabetic patients aged 18 and over. Based on the established Dexcom CGM platform, Dexcom's G7 boasts 15 days of wear and best-in-class accuracy.
Icotrokinra cleans skin among 75% of adolescents with plaque psoriasis
In a subgroup analysis of the iconic lead randomized controlled trial of phase 3, adolescents with moderate to severe plaque psoriasis treated with Icotrokinra (JNJ-2113) one day (JNJ-2113) acquired a higher percentage or nearly clear skin at 16 weeks compared to placebo. Icotrokinra exhibits a favorable safety profile, achieving a lower adverse event rate (50% vs. 73%) than placebo, with no new safety signals reported.
